Phase 2 N=10 STAR Cape+BKM120 MBC With Brain Met
Brain Metastases · Breast Cancer · Metastatic Breast Cancer
Primary: Clinical Benefit Rate (CBR) — 0.1 proportion of patients with CBR
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=28 Brain Irradiation and Tremelimumab in Metastatic Breast Cancer
Metastatic Breast Cancer
Primary: Progression Free Survival (irPFS) — 21; 1; 3; 1 Participants
Phase 2 N=242 Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer
Neoplasms, Breast
Primary: The Number of Participants With Central Nervous System (CNS) Best Overall Response — 0; 0; 6; 9 Participants
Phase 2 N=38 Carboplatin and Bevacizumab for Progressive Breast Cancer Brain Metastases
Metastatic Breast Cancer · Breast Cancer · Progressive Breast Cancer
Primary: Central Nervous System (CNS) Objective Response Rate — 63 percentage of participants
Phase 2 N=24 TPI 287 in Breast Cancer Metastatic to the Brain
Breast Cancer
Primary: Overall Response Rate (ORR) — 21 Participants
Phase 2 N=9 Treatment of Brain Metastases From Breast Cancer With Eribulin Mesylate
Metastatic Breast Cancer · Brain Metastases
Primary: Percent of Participants With Central Nervous System (CNS) Progression Free Survival (PFS) — 88.9 percentage of participants
Phase 2 N=143 Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer
HER2-Positive Breast Carcinoma · Invasive Breast Carcinoma · Metastatic Malignant Neoplasm in the Brain
Primary: Complete Response (CR) Rate in the Brain at 12 Weeks Post-radiation Therapy (RT) Using the RECIST 1.1 Criteria Based on Brain Magnetic Resonance Imaging (MRI) — 5.8; 0…
Phase 2 N=36 Cabozantinib +/- Trastuzumab In Breast Cancer Patients w/ Brain Metastases
Breast Cancer · Brain Tumor - Metastatic
Primary: CNS Objective Response Rate (ORR) — 5; 14; 0 percentage of participants
N/A N=22 Whole Brain Radiation Therapy With Boost to Metastatic Tumor Volume Using RapidArc
Neoplasm Metastasis
Primary: Percent of Participants With Locoregional Control of Treating Brain Metastasis Patients — 92; 98.6; 46; 46 percentage of participants
Phase 2 N=140 HKI-272 for HER2-Positive Breast Cancer and Brain Metastases
Breast Cancer
Primary: Objective Response Rate Per Composite Response Criteria — 7.5; 48.6; 33.3 percent of participants
Phase 2 N=30 Irinotecan and Temozolomide in Treating Patients With Breast Cancer Who Have Received Previous Treatment for Brain Metastases
Breast Cancer · Metastatic Cancer
Primary: Number of Patients With Objective Treatment Response (Complete or Partial) in the CNS — 2 Participants
Phase 2 N=17 Carboplatin and Temozolomide (Temodar) for Recurrent and Symptomatic Residual Brain Metastases
Brain Tumor · Brain Metastases
Primary: Affects of Response Rate of Chemotherapy With Intra-arterial Carboplatin and Oral Temozolomide — 42.8 percentage of patients with response
N/A N=40 Stereotactic Radiation Therapy in Treating Patients With Brain Metastases
Metastatic Cancer · Unspecified Adult Solid Tumor, Protocol Specific
Primary: Proportion of Patients Dying of Neurological Death, Defined as Dying With Progressive Neurological Dysfunction Regardless of Systemic Disease Status — 5 patients
Phase 1 N=35 Lapatinib in Combination With Radiation Therapy in Patients With Brain Metastases From HER2-Positive Breast Cancer
Breast Cancer · Brain Metastases
Primary: The Maximum Tolerated Dose of Lapatinib When Combined With Cranial Radiation in Patients With CNS Metastases From HER2-positive Breast Cancer. — 1250 milligrams
Phase 2 N=55 Epothilone B in Treating Patients With CNS Metastases From Breast Cancer
Breast Cancer · Metastatic Cancer
Primary: Central Nervous System (CNS) Progression-free Survival(PFS) — 12; 2 participants
Phase 3 N=129 Testing Whether Treating Breast Cancer Metastases With Surgery or High-Dose Radiation Improves Survival
Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8 · Metastatic Breast Carcinoma · Metastatic Malignant Neoplasm in the Bone
Primary: Progression-free Survival (Phase II) — 23.0; 19.5 months — p=0.36
Phase 3 N=213 Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
Breast Cancer · Cognitive/Functional Effects · Lung Cancer
Primary: Neurocognitive Progression as Measured by the Number of Participants With Cognitive Deterioration by 3 Months — 40; 44 Participants — p=<0.001
Phase 2 N=6 Atezolizumab + Stereotactic Radiation in Triple-negative Breast Cancer and Brain Metastasis
Breast Cancer
Primary: Progression-Free Survival — 5.8 weeks
N/A N=52 MRI Study of Changes in Blood-Brain/Tumor-Barrier Permeability in Patients With Brain Metastases During and After Radiotherapy
Brain Metastases
Primary: Percentage of the Gross Tumor Volume With a BTB Opening of Ktrans > 0.005 Min-1 — 78.6; 85.6; 6.4; 74.4 percentage of gross tumor volume
Phase 2 N=32 A Study Of Everolimus, Trastuzumab And Vinorelbine In HER2-Positive Breast Cancer Brain Metastases
HER-2 Positive Breast Cancer
Primary: Intracranial Objective Response Rate- Modified RECIST Criteria — 0; 1; 17; 8 Participants
Phase 2 N=51 Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases
Brain Metastasis · Bladder Cancer · Breast Cancer
Primary: Local Control — 13; 23; 2; 1 participants
N/A N=13 Managing Distress in Malignant Brain Cancer
Cancer Metastatic to Brain · Brain Metastases, Adult
Primary: Assess the Need for Adaptations to the CALM Intervention as Measured by the Applicability of the 4 CALM Domains — 3.2; 4.0; 4.0; 3.5 score on a scale
N/A N=2 F18 EF5 PET/CT Imaging in Patients With Brain Metastases From Breast Cancer
Brain Metastases From Breast Cancer
Primary: Number of Participants With Adverse Events — 0 Participants
N/A N=17 18F-FLT-PET Imaging of the Brain in Patients With Metastatic Breast Cancer to the Brain Treated With Whole Brain Radiation Therapy With or Without Sorafenib: Comparison With MR Imaging of the Brain
Metastatic Breast Cancer to the Brain
Primary: Overall Response Rate — 71 % of pts w/complete or partial response
N/A N=41 A Proof-of-principle Study of HBO-SRS for Brain Metastases
Brain Metastases
Primary: The Average Time From HBO Chamber Exit to SRS beam-on — 8.3 minutes
Phase 2 N=27 Bevacizumab in Pats w/ Recurrent ST Brain Metas Who Have Failed Whole Brain Radiation Therapy
Metastatic Cancer · Unspecified Adult Solid Tumor, Protocol Specific
Primary: Objective Radiographic Tumor Response in Patients With Recurrent Solid Tumor Brain Metastases Treated With Bevacizumab — 2 Participants
Phase 3 N=472 Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer
Lung Cancer, Non-Small Cell
Primary: Overall Survival — 4.0; 3.6 months — p=0.1862
N/A N=90 Primary Operation in SYnchronous meTastasized InVasivE Breast Cancer
Synchronous Metastasized Breast Cancer · Circulating Tumor Cells
Primary: Overall Survival (OS) — 34.6; 56.2 months — p=0.042
Phase 2 N=55 Whole Brain Radiotherapy With or Without Temozolomide at Daily Fixed-dose for Brain Metastases Treatment
Brain Neoplasms
Primary: Objective Response Rates. Assessed With Cranial MRI — 78.6; 48.1 Percentage of participants with OR — p=0.019
Phase 2 N=3 Liposomal Cytarabine and High-Dose Methotrexate in Treating Patients With Central Nervous System Metastases From Breast Cancer
Central Nervous System Metastases · Leptomeningeal Metastases · Recurrent Breast Cancer
Primary: Survival Free of Neurological Progression, Measured in Weeks — 6 weeks